A steroidal compound was recently detected in a seized black market product and was identified as (17α,20E)‐17,20‐[(1‐methoxyethylidene) bis (oxy)]‐3‐oxo‐19‐norpregna‐4,20‐diene‐21‐carboxylic acid methyl ester (YK11). This compound is described to possess selective androgen receptor modulator‐ and myostatin inhibitor‐like properties. As YK11 is an experimental drug candidate and a non‐approved substance for humans, scientific data on its metabolism is scarce. Due to its steroidal backbone and the arguably labile orthoester‐derived moiety positioned at the D‐ring, substantial metabolic conversion in vivo was anticipated.
In order to unambiguously detect urinary metabolites of YK11, an elimination study with six‐fold deuterated YK11 was conducted. Post administration specimens were analyzed using hydrogen isotope ratio mass spectrometry coupled to single quadrupole mass spectrometry to identify metabolites alongside basic mass spectrometric data. Further characterization of those metabolites relevant to sports drug testing was accomplished using gas chromatography/high resolution‐high accuracy mass spectrometry.
Fourteen deuterated urinary metabolites were detected comprising unconjugated, glucuronidated and sulfoconjugated metabolites. As expected, no intact YK11 was observed in the elimination study urine samples. While the unconjugated metabolites disappeared within 24 h post‐administration, both glucuronidated and sulfated metabolites were traceable for more than 48 h. The chemical structures of the two most promising glucuronidated metabolites (5β‐19‐nor‐pregnane‐3α,17β,20‐triol and 5β‐19‐nor‐pregnane‐3α,17β‐diol‐20‐one) were verified by in‐house synthesis of both metabolites and verified by NMR analysis. In order to elucidate their potential in sports drug testing, both were successfully implemented into the currently applied analytical method for the detection of anabolic agents.